Olga Potapova is an expert in biotechnology, life sciences, business development, and international alliance management. Since 2003, Dr. Potapova is leading the Cureline Group with excellence in the area of precision medicine, translational medicine research and laboratory services. Previously she worked in the fields of cancer research (NIH and Pfizer/SUGEN), human molecular genetics and genomics, oncology drug R&D, and translational medicine. Since 2010 Dr. Potapova is the TCGA and CPTAC (NIH, USA) Principal Investigator. She has advanced degrees in Physics and Biochemistry and has received multiple AACR/AFLAC awards, NIH and NATO fellowships.

Agne Vaitkeviciene holds a BS in molecular biology (Vilnius University,
Lithuania) and MS in organ, tissue and cell donation (University of Barcelona,
Spain). Since 2006 she has been working in the field of cell therapy as a
quality assurance specialist. In 2013 Agne Vaitkeviciene co-founded life
science startup company and managed its activities in the field of
advanced therapy medicinal product research and manufacturing as CEO
until 2019. Since 2019 she is actively involved as an expert in EU programs,
such as IMI2, EIT Health Innostarts and consults biotechnology companies in
life science product development management. For the last 3 years Agne
Vaitkeviciene has been actively involved in life science expert groups within
governmental organizations such as “Enterprise Lithuania”, Science,
Innovation and Technology Agency, “Invest Lithuania” and others. Lithuanian
biotechnology association elected Agne as a vice-president in 2019 and
delegated responsibilities of coordinating foreign affairs and startup support
activities within the association. In 2020 Agne Vaitkeviciene became an
executive director of Lithuanian biotechnology association.

Laura obtained her Masters in Pharmacy at Lithuanian University of Health Sciences. As a PhD candidate at Lithuanian University of Health Sciences, in her thesis she mainly focuses on metabolism and communication between immune and cancer cells within tumor microenvironment. Her key strengths is in vitro and in vivo experiments design, preclinical research execution and management. She also has experience in cell therapy Startup, developing ATMPs from bench to bedside.